Immunocore to Announce Key Financial Results and Webinar Event

Author: Evelyn Baker Updated: 02-19-2025 07:10 AM

Immunocore Financial Results Announcement

Immunocore Holdings plc (NASDAQ: IMCR), a pioneering biotechnology company, specializes in creating immunomodulating medications that significantly enhance the treatment outcomes for patients suffering from cancer, infections, and autoimmune disorders. The company is set to release its financial performance for the fourth quarter and the entire 2024 fiscal year on February 26, 2025.

Live Teleconference and Webcast

Alongside the financial report, Immunocore will conduct a live teleconference and webcast starting at 8:00 a.m. EST (1:00 p.m. GMT). This session will provide insights into the company’s financial results and offer updates on its business strategies and product portfolio.

How to Access the Webcast

The live call will be accessible through the 'Events' section on Immunocore’s official website, under the 'Investors' area. A replay of the event will be made available shortly after, ensuring that stakeholders and interested parties can stay informed.

Conference Call Information

For those wishing to join, the details are as follows: For domestic participants, the toll-free number is 877-405-1239, and international callers can reach +1 201-389-0851.

About Immunocore's Innovative Therapies

Immunocore is at the forefront of biomedicine, developing a unique class of therapies known as ImmTAX – Immune mobilizing monoclonal TCRs Against X diseases. These therapies target a variety of conditions, including cancers, autoimmune diseases, and infectious diseases. Utilizing its proprietary ImmTAX platform, the company is cultivating a comprehensive pipeline that addresses several therapeutic areas.

Regulatory Approvals and Product Advancement

Immunocore’s flagship oncology treatment, KIMMTRAK, has gained approval for treating adult patients with metastatic or unresectable uveal melanoma who are positive for HLA-A*02:01. The company is committed to expanding this treatment to additional patient populations through ongoing research and potential new indications.

Strategic Vision for 2025

As Immunocore approaches 2025, it remains focused on fulfilling its strategic objectives while ambitively pursuing the advancement of its clinical pipeline. This includes their intent to broaden the availability of KIMMTRAK and explore new opportunities for additional therapeutic applications.

Contact Immunocore

The public is encouraged to connect with Immunocore for further inquiries: Sébastien Desprez leads the communications team and can be reached at +44 (0) 7458030732 or via email at sebastien.desprez@immunocore.com.

For investor relations, reach out to Clayton Robertson or Morgan Warenius at +1 (215) 384-4781 or by emailing ir@immunocore.com.

Frequently Asked Questions

What financial results will Immunocore release?

Immunocore will disclose its financial outcomes for the fourth quarter and the full year ended December 31, 2024.

When is the financial call scheduled?

The financial call is scheduled for February 26, 2025, at 8:00 a.m. EST.

How can I access the live teleconference?

The teleconference can be accessed through the 'Events' section on the Immunocore website.

Who can I contact for more information?

For inquiries, you can contact Sébastien Desprez at Immunocore.

What is KIMMTRAK?

KIMMTRAK is an innovative therapy developed by Immunocore aimed at treating specific types of cancer, particularly metastatic uveal melanoma.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.